Comparative in vitro antibacterial analysis of different brands of cefixime against clinical isolates of Staphylococcus aureus and Escherichia coli

Journal of Applied Pharmaceutical Science

Volumn 2, Issue 1, 2012, Pages 109-113

  Arshad, Hafiz Muhammad ^a   Mohiuddin, Omair Anwar ^a   Azmi, Muhammad Bilal ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Antibacterial; Cefixime; Clinical isolates; E. coli; Mueller hinton broth; S. aureus

Indexed keywords

EID: 84864276375     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Anacona J.R., Estacio J. Synthesis and Antibacterial Activity of Cefixime Metal Complexes. Transition Metal Chem. 2006; 31: 227-231.
2. Barry A.L., Pfaller M.A., Fuchs P.C., Packer P.R. Therapy of multidrug resistant typhoid fever with oral Cefixime vs. intravenous ceftrixone. Pediatr Infect Dis J. 1994; 13: 990.
3. Bowie W.R., Shaw C.E., Chan D.G.W. In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and Cefixime (CL 284,635; FK 027) against selected genital pathogens. Antimicrob Agents Chemother. 1986; 30:590-593.
4. Dagan R., Einhorn M., Lang R. Once daily Cefixime compared with twice daily trimethoprim/sulfamethoxazol for the treatment of urinary tract infection in infants and children. Pediatr Infect Dis J. 1992; 11:196-203.
5. Edelstein D.R., Avner S.E., Chow J.M. Once a day therapy for sinusitis: a comparison study of Cefixime and amoxicillin. Laryngoscope. 1993; 103:33-41.
6. Gelone S and O'Donnell J.A. Anti - Infectives. In: Remington 'The Science and Practice of Pharmacy' 21st ed. Lippincott Williams and Wilkins (2005) 1644.
7. Gennaro A.R. Remington Pharmaceutical 17th Ed. Mac Publishing Co., (1985) 1184.
8. Guay D.R., Meatherall R.C., Harding G.K., Brown G.R. Pharmacokinetics of Cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 1986; 30(3): 485-90.
9. Gums J.G. Assessing the impact of antimicrobial resistance. Am. J. Healthm Syst. Pharm. 2002; 59(3): 4-6.
10. Hammerum A.M., Heuer O.E. Human Health Hazards from Antimicrobial-Resistant Escherichia coli of Animal Origin. Clin Infec Dis. 2009; 48: 916-21.
11. Hannan A., Saleem S., Chaudhary S., Barkaat M., Arshad M.U. Anti Bacterial Activity of Nigella Sativa against Clinical Isolates Of Methicillin Resistant Staphylococcus Aureus. J Ayub Med Coll Abbottabad. 2008; 20(3).
12. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing gramnegative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program. Antimicrob. Agents Chemother. 2007; 53(8): 3280-3284.
13. Ikeda F., Yokota Y., Mine Y., Tatsuta M. Activity of Cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins. Antimicrob Ag Chemother. 1990; 34: 2426.
14. Ison C.A., Alexander S. Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. Expert Rev Anti Infect Ther. 2011; 9(10): 867-76.
15. Jeong S.H., Song W., Kim J.S., Kim H.S., Lee k. Broth microdilution method to detect extended-spectrum -lactamases and AmpC -lactamases in Enterebacteriaceae isolates by use of clavulanic acid and boronic acid as inhibitors. J. of Clinical Microbiol. 2009; 47(11): 3409-3412.
16. Khan N.V., Hassan F., Naqvi B.S., Hasan S.M.F. Antimicrobial Activity Of Erythromycin And Clarithromycin Against Clinical IsolatesOf Escherichia Coli, Staphylococcus Aureus, Klebsiella And Proteus By Disc Diffusion Method. Pak. J. Pharm. Sci. 2011; 24(1): 25-29.
17. Kunel'skaya N.L., Gurov A.V., Kudriavtseva I.S., Kafarskaia L.I., Izotova G.N. Study of the efficacy of cefixime (suprax) in patients with acute and recurrent chronic purulent sinusitis]. Vestn Otorinolaringol. 2008; 6: 55-8.
18. Memon I.A., Billoo A.G., Memon H.I. Cefixime an oral option for the treatment of multidrug-resistant enteric fever in children. South Med J. 1997; 90(12): 1204-7.
19. Mesnard R., Donnio P.Y. In vitro activities of Penicillin, Amoxycillin and certain cephalosporin, including Cefpodoxime against human isolates of Pasteurellia multocida. J. Antimicrob Chemother. 1991; 28: 483.
20. Mortensen J.E., Himes S.L. Comparative invitro activity of Cefixime against Haemophilus influenzae isolates from pediatric patients. Antimicrob Ag Chemother. 1990; 34: 1456.
21. Naqvi I., Saleemi A.R., Navee S. Cefixime: A drug as Efficient Corrosion Inhibitor for Mild Steel in Acidic Media. Electrochemical and Thermodynamic Studies. Int. J. Electrochem. Sci. 2011; 6: 146-161.
22. Nash D.R., Flanagan C., Steele L.C., Wallace R.J. Jr. Comparison of the activity of Cefixime and activities of other oral antibioticsagainst adult clinical isolates of Moraxella (Branhamela) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae". Antimicrob Ag Chemother. 1991; 35: 192.
23. Neu H.C. In Vitro activity of new broad spectrum, beta - lactamase- stable oral Cephalosporin Cefixime Pediatric Infection Dis. J. 1987; 6: 958-962.
24. Petri W.A. Penicillins, Cephalosporins, and other fi- Lactam antibiotics. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th eds. U.S.A: McGraw- Hill Co. Incorp (2006).
25. Pfaller M.A., Messer S.A., Mills K., Bolmstro M.A., Jones R.N. Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida Specie. Journal of Clinical Microbiology. 2001; 39(12): 4387-438.
26. Powell M., Williams J.D. In vitro susceptibility of haemophilus influenzae to Cefixime". Antimicrob Agents Chemother. 1987; 31:1841-1842.
27. Rafal'skiǐ V.V., Divgan' E.V., Derevitskiǐ A.V. Cefixim: clinical pharmacology and role in therapy of urogenital infections. Urologiia. 2011; 2: 63-6.
28. Roche G. Cefixime, the first oral third-generation cephalosporins. Presse Med. 1989; 18(32): 1541-4.
29. Sakata T., Miyake K., Kinukawa T., Hattori R., Obata K., Otani T., Narushima M., Ito Y., Takita T. Clinical evaluation of usefulness of Cefixime (200 mg administered once daily) in the treatment of acute uncomplicated cystitis. Hinyokika Kiyo. 1992; 38(11): 1337-42.
30. Stone J.W., Linong G., Andrews J.M., Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration". J Antimicrob Chemother. 1989; 23: 221
31. Wilson and Gisvold. "Text book of organic and medicinal and pharmaceutical chemistry", 10 Edition (1998) 287.
32. Wu D.H. A review of the safety profile of Cefixime. Clin Ther. 1993; 15(6): 1108-19.